Abstract
The association between atopic dermatitis (AD) and malignancy has had ongoing interest. In this issue of BJD Wan et al. present findings from a large cohort study, confirming heterogenous effects by malignancy sub type. AD was associated with non-melanoma skin cancer (NMSC), potentially explained by lower filaggrin levels or use of immunosuppressive treatments. There is renewed attention to cancer risk in AD, since use of JAKis has been associated with an increased risk of NMSC and EMA has restricted JAKi use in specific patient populations including those with risk factors for malignancy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
